Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.77 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.77 |
| ▸ | FLT1 | P17948 | 1/20 | 0.77 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | JAK1 | P23458 | 2/20 | 0.44 |
| ▸ | TYK2 | P29597 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2858236 | 0.88 | KDR (0.79) | KDRKITKCNH2PDGFRBFLT1 | |
| SCHEMBL2865607 | 0.88 | KDR (0.78) | KDRKITKCNH2PDGFRBFLT1 | |
| SCHEMBL2865487 | 0.88 | KDR (0.78) | KDRKITKCNH2PDGFRBFLT1 | |
| SCHEMBL2866810 | 0.88 | KDR (0.78) | KDRKITKCNH2PDGFRBFLT1 | |
| SCHEMBL2865493 | 0.88 | KDR (0.78) | KDRKITKCNH2PDGFRBFLT1 | |
| SCHEMBL2861987 | 0.87 | KDR (1.00) | KDRKITKCNH2PDGFRBFLT1 | |
| SCHEMBL2855384 | 0.87 | KDR (1.00) | KDRKITKCNH2PDGFRBFLT1 | |
| SCHEMBL2859332 | 0.87 | KDR (0.77) | KDRKITKCNH2PDGFRBFLT1 | |
| SCHEMBL2866416 | 0.84 | KDR (0.72) | KDRKITKCNH2PDGFRBFLT1 | |
| SCHEMBL2864843 | 0.80 | KDR (0.81) | KDRKITKCNH2PDGFRBFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513818-B1 | HETEROCYCLIC INHIBITORS OF VEGFR-2 KINASES | BRISTOL MYERS SQUIBB CO (US) | 2010-01-20 | — | — | EP | claimed |
| EP-1513818-A4 | HETEROCYCLIC INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-10-04 | — | — | EP | claimed |
| US-20060135576-A1 | Heterocyclic inhibitors of kinases | BORZILLERI ROBERT M | 2006-06-22 | — | — | US | claimed |
| EP-1513818-A2 | HETEROCYCLIC INHIBITORS OF KINASES | Bristol-Myers Squibb Company (US) | 2005-03-16 | — | — | EP | claimed |
| US-20040077696-A1 | Heterocyclic inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | claimed |
| WO-2004001059-A2 | HETEROCYCLIC INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-31 | — | — | WO | claimed |
| EP-1513818-B1 | HETEROCYCLIC INHIBITORS OF VEGFR-2 KINASES | BRISTOL MYERS SQUIBB CO (US) | 2010-01-20 | — | — | EP | disclosed |
| US-7547711-B2 | Heterocyclic inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547711-B2 | Heterocyclic inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547711-B2 | Heterocyclic inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| EP-1513818-A4 | HETEROCYCLIC INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-10-04 | — | — | EP | disclosed |
| US-7084160-B2 | Heterocyclic inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060135576-A1 | Heterocyclic inhibitors of kinases | BORZILLERI ROBERT M | 2006-06-22 | — | — | US | disclosed |
| EP-1513818-A2 | HETEROCYCLIC INHIBITORS OF KINASES | Bristol-Myers Squibb Company (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040077696-A1 | Heterocyclic inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| WO-2004001059-A2 | HETEROCYCLIC INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135576-A1 | Heterocyclic inhibitors of kinases | FGFR1, FLT1, FGFR2 | KDR 7/4885KIT 167/4885KCNH2 2927/4885 |
| US-20040077696-A1 | Heterocyclic inhibitors of kinases | FGFR1, FLT1, FGFR2 | KDR 6/4885KIT 136/4885KCNH2 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.